SecBot SecBot
PRESS-RELEASE ·Filed Nov 15, 2026

HCM

HUTCHMED (China) Limited
NEUTRAL
Impact 4/10
Horizonmonths Processed1d 4h ago WireGlobeNewswire
Press release · Contract
Actionable Insight • Neutral

Monitor HUTCHMED's upcoming quarterly filings for any changes in revenue trends for ELUNATE, ORPATHYS and SULANDA following the expanded NRDL coverage. The renewal removes near-term reimbursement risk for these products.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

HCM drug pipeline →

ORPATHYS

◆ Mixed Named in this press release
Impact
Phase
Approved in China (3 indications); global Phase 3 readout pending
Time to market
Already approved and marketed in China (lung cancer since 2021, gastric cancer July 2026). Ex-China (US/EU) approval is not filed yet — timing hinges on the SAFFRON global Phase 3 readout expected H2 2026.
Next catalyst
None dated

What to watchWatch for SAFFRON/SANOVO Phase 3 topline data in H2 2026, a positive readout supports global (ex-China) filings for savolitinib and would be the biggest near-term share-price lever; a miss or delay would hit a stock already near its 52-week low ($11.13 vs $18.30 high). HUTCHMED carries $1.37B cash, so the stock isn't a financing story, but this one drug's readout is the dominant H2 catalyst alongside sovleplenib NDA decisions.

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

HUTCHMED announced that three of its drugs (ELUNATE, ORPATHYS, SULANDA) will continue to be included in China's National Reimbursement Drug List (NRDL) effective January 1, 2027, with expanded coverage for new indications. This renewal supports ongoing commercial access and revenue from these products in China.

Key Facts

  • ELUNATE (fruquintinib) newly included for renal cell carcinoma in combination with sintilimab
  • ORPATHYS (savolitinib) newly included for EGFR-mutant NSCLC with MET amplification, in combination with osimertinib
  • ORPATHYS renewed for NSCLC with MET exon 14 skipping alteration
  • All previously included indications for ELUNATE, ORPATHYS and SULANDA maintained under multi-year agreements
  • Updated NRDL effective January 1, 2027

Financial Impact

No financial figures provided; NRDL inclusion supports continued revenue from these drugs in China but pricing and volume impact not disclosed.

revenue

Risk Factors

  • NRDL inclusion involves pricing negotiations that could pressure margins
  • Competition from other targeted therapies in the same indications
  • Reliance on China's annual NRDL renewal process for continued access

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (26 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3403144

Track record

33 reports on HCM

Performance horizon

8 of 9 bullish or bearish reports moved the stock their way by T+60. Best: +38.35% at T+60 after the Jun 25, 2026 report. 18 of 23 went positive at some point.

Filters
  1. Nov 15, 20261d ago Press Release Neutral 4/10 Viewing Entry $14.90 Now $14.73 −1.14% settles Feb 12
  2. Nov 5, 202611d ago 6-K Bullish 5/10 Entry $14.20 Now $14.73 +3.73% settles Feb 3
  3. Nov 2, 202614d ago 6-K Bullish 6/10 Entry $13.27 Now $14.73 +11.00% settles Jan 29
  4. Nov 2, 202615d ago Press Release Bullish 6/10 Entry $13.08 Now $14.73 +12.61% settles Feb 1
  5. Oct 29, 202618d ago 6-K Neutral 4/10 Entry $13.59 Now $14.73 +8.39% settles Jan 27
  6. Oct 27, 202620d ago 6-K Neutral 2/10 Entry $13.80 Now $14.73 +6.74% settles Jan 25
  7. Oct 26, 202621d ago 6-K Bullish 6/10 Entry $14.27 Now $14.73 +3.22% settles Jan 22
  8. Oct 26, 202621d ago Press Release Bullish 7/10 Entry $14.27 Now $14.73 +3.22% settles Jan 22
  9. Oct 26, 202622d ago Press Release Bullish 7/10 Entry $13.80 Now $14.73 +6.74% settles Jan 25
  10. Oct 21, 202626d ago 6-K Bullish 7/10 Entry $14.37 Now $14.73 +2.51% settles Jan 19
Showing 10 of 33

US Market Status

Market Closed · Opens in 6h 8m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 15, 2026